Clinical improvement of diabetes mellitus type 1 by b-D-mannuronic acid (M2000) in a breast cancer patient — as a case report

A 56 years old female with breast cancer (BC) and poor controlled diabetes mellitus type 1 (DM1) which has registered in a clinical trial for assessment of thera­peutic efficacy of b-D-mannuronic acid (M2000) on pre-surgical BC patients is described in this case report. After receiving M2000, the patient was followed for 9 weeks. During this period, cancer mass details, fast­ing blood glucose (FBG) levels, 2-hour post-prandial blood glucose (2HPP), blood uric acid (BUA) level and urine analysis (UA) were continuously controlled. After 9 weeks of treatment with M2000, her FBG, BUA and UA decreased significantly. This finding was exactly in accordance with our published experimental data about the anti-diabetic effect of M2000 in an animal model. Therefore, it might be concluded that M2000 is probably able to improve DM1 by reducing FBG level, BUA level, glycosuria, ketonuria and proteinuria.

[1]  A. Mirshafiey,et al.  Anti-diabetic effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the experimental diabetes model , 2018, Archives of physiology and biochemistry.

[2]  A. Mirshafiey,et al.  Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model , 2018, Immunopharmacology and immunotoxicology.

[3]  A. Mirshafiey,et al.  Anti-inflammatory Property of β-D-Mannuronic Acid (M2000) on Expression and Activity of Matrix Metalloproteinase-2 and -9 through CD147 Molecule in Phorbol Myristate Acetate-differentiated THP-1 Cells. , 2017, Iranian journal of allergy, asthma, and immunology.

[4]  S. Cuzzocrea,et al.  Introduction of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression , 2017, Pharmacological reports : PR.

[5]  S. E. Enderami,et al.  Targeting of crosstalk between tumor and tumor microenvironment by β‐D mannuronic acid (M2000) in murine breast cancer model , 2017, Cancer medicine.

[6]  G. Ren,et al.  Diabetes mellitus and prognosis in women with breast cancer , 2016, Medicine.

[7]  Yi-Min Zhu,et al.  Diabetes and cancer: Associations, mechanisms, and implications for medical practice. , 2014, World journal of diabetes.

[8]  Rachel V. Stankowski,et al.  Diabetes and cancer I: risk, survival, and implications for screening , 2012, Cancer Causes & Control.

[9]  S. Cuzzocrea,et al.  M2000: a revolution in pharmacology. , 2005, Medical science monitor : international medical journal of experimental and clinical research.